Modern public healthcare accentuates the importance of professional capacities of pharmacists from the perspective of their engagement in integrated and evidence-based pharmaceutical practice. Such practice is expected to expand towards and consolidate existing expertise in the areas of responsible use of medicines, innovation, disease prevention and treatment. This will also involve cooperation with other healthcare practitioners, and above all, with patients (FIP, 2011) . With the onset of the development of modern pharmaceutical care, the findings garnered within the field of clinical pharmacy have been progressively applied to the practice of community pharmacies. This means that, along with hospital and clinical pharmacists, the pharmacists practicing in community pharmacies are also continuously becoming more engaged in dealing with drug related problems (DRPs) (PCNE, 2006) . The most common problems include drug interactions, adverse effects and dosage regimes, but the pharmacists' attention is also continuously shifting towards issues of medication adherence. Adherence of patients to treatment is a fundamental requirement for achieving therapeutic effect. Not complying with a prescribed therapeutic regime leads to therapeutic failure and increased costs for the treatment of diseases (Kriška et al., 2015 , Spinewine et al., 2012 . It is a well-known worldwide problem that not only affects acute illnesses, but more frequently chronic diseases. According to the WHO (2003) , up to 50% of chronically ill patients do not comply with the recommended treatment regime. Therefore, innovative and more effective multidisciplinary approaches are being sought that would improve patients´ adherence, built upon an equal relationship with patients and the systematic improvement of patients' health literacy (Spinewine et al., Taitel et al., 2012) . A promising approach is to link adherence with pharmacovigilance, which has become an indispensable part of the responsible use of medicines (Leporini, 2014 , Sun et al., 2014 . In practice, interventions are used to improve medication adherence; recently, with the help of wireless and mobile technologies, for instance, to improve dosage regimes (Středa & Hána, 2016) . Essentially, there is an increasing array of evidence that non-adherence can be effectively tackled by two complementary approaches: firstly, via a multidisciplinary approach, and secondly, via electronic and computerized healthcare systems (e-Health). If pharmacists are to be a part of this, monitoring and systemic support of medication adherence should become one of the priorities of their practice and of drug dispensation related activities. Despite continuous scientific evaluation of pharmacists' involvement in DRPs, medication adherence including, treatment satisfaction and patient education programs, only a limited number of studies have been performed concerning the role of community pharmacists in DRPs in the Czech (CZ) and Slovak (SK) Republics (Masaryková et al., 2014 , Vlček et al., 2009 . A review of the existing literature reveals that there has been no research whatsoever on medication adherence support or on the reduction of non-adherence risks by community pharmacists (this is also the case specifically with regards to the technical and personnel capacities of community pharmacies). Therefore, further investigations conducted in this area could rectify this lacuna. This work has a character of a pilot study. It might contribute to the evaluation of hypothesis on a non-adherence risk reduction by pharmacists and detection in which form and with what intensity medication adherence could be supported by community pharmacists in CZ and SK. In addition, we have also focused on counselling and consultations provided by pharmacists in order to determine personnel and technical factors of pharmacies that may correlate with support for adherence in both countries.
MEthodS

Study design and participants
Questionnaire survey on adherence support was provided by 158 community pharmacists from CZ and SK community pharmacies in a period from November till December of 2014. The CZ data set was composed of 117 community pharmacists (one pharmacist from one community pharmacy), that represented 56.5% of 207 pharmacies grouped in the association of independent pharmacists and in cooperation with the Faculty of Pharmacy in Hradec Králové, Charles University. From a geographical perspective, all 14 regions of CZ were covered. The SK data set was composed of 41 community pharmacists (one pharmacist representing one community pharmacy) out of 128 (31.8%) that we approached via students of the Faculty of Pharmacy, Comenius University in Bratislava) undertaking their mandatory practice there. From a geographical perspective, 7 out of 8 regions of SK were covered. We are conscious of the fact that there is no specification of the Good Pharmacy Practice, which would be available exclusively for the selected data sets of CZ and SK pharmacists-responders, as compared to other CZ and SK community pharmacists, and could therefore represent a systematic error in this regard. We used a structured questionnaire in the Czech and Slovak languages to estimate the pharmacists' support for medication adherence. The questionnaire was addressed to the heads of pharmacies or to their deputies, who answered about their practice in a specific pharmacy. It contained 15 questions divided into 5 categories that enabled us to map the basic characteristics of pharmacies, such as a geographic distribution, size, as well as specific technical and personnel factors. The aim was to examine the intensity and extent of pharmaceutical patient-oriented care from the perspective of the pharmacists taking part in this survey, regarding the surveyed medication adherence promotion provided in a pharmacy. The questionnaire was available online (Fig. 1) . 
Structure of the questionnaire
Statistical methodology
To process the results of the questionnaires, we used methods of descriptive and inductive statistics. The core of the questionnaire was formed around the questions of a dichotomic or polytomic character. The final quantities were summarized in a contingency table. To test associations, we used the chi-squared test (χ 2 ) or exact tests (Fisher and FisherFreeman-Halton tests). The differences between groups were tested by the t-test and, in relevant cases, by non-parametric methods (Mann-Whitney test for analysis of variations). We analysed the degree of associations with correlation coefficients: Cramér's V and Goodman and Kruskal's gamma. For certain comparisons, we introduced an odds ratio (OR) with the respective confidence interval, 95% (95% CI). In all Note: Non-adherence could be spontaneous, intentional or unintentional. Spontaneous non-adherence is usually caused by forgetfulness and is usually solved by continuous reminding that is linked to usual daily activities and medicines dispensers. Intentional non-adherence is a deliberate non-complying with the recommended treatment.
13. In what manner do you usually offer support for adherence? (multiple choice is possible) a) we provide information about use of medicine b) we provide the information related to the use of medicine and verify if the patient understands the information c) we recommend to patient his/her appropriate system to monitoring and recording use of medicines d) other (please specify) e) we do not offer such support Note: Adherence means an affirmative attitude on behalf of patient towards treatment, acting in accordance with the pharmacotherapy recommended by the healthcare practitioner. It significantly influences the therapeutic value of the prescribed medicine.
14. In what manner do you offer support for persistence -continuity of treatment -throughout the recommended period of therapy? (multiple choice is possible) a) we engage the patient by asking questions related to his or her readiness to undertake a long-term treatment b) we agree with the patient on a continuous cooperation c) we communicate with a medical practitioner in case we have suspect that the patient deliberately adjusts the length of the recommended pharmacotherapy d) other (please specify) e) we do not offer such support Note: Persistence -means continuity throughout the entire treatment (i.e. patient uses medicine throughout the entire therapy).
15. How do you increase trust in patients in order to achieve their concordance? (multiple choice is possible) a) we provide personal counselling related to the selected drug form, application and dosage b) we consult with patient the recommended medication dose titration (e.g. due to skin irritation) c) we identify with the patient his or her options for a routine use of medicines in accordance with the maintenance therapy recommended by a medicine practitioner (e.g. system of notifications, personal monitoring and recording) d/ we engage the patient in different way (please specify): e) we do not deal with such issue Note: Concordance means a partnership between patient and pharmacist that leads to an agreement on why and how to use the relevant medicines. Unlike compliance, concordance represents an agreement based on a patient's own conviction, reached as a result of an individual approach and it is based on the provision of adequate information, including an explanation of the expected therapeutic effect and adverse effects, the costs of treatment and other relevant factors.
cases, we tested at a significance level of alpha ≤0.05. We performed the analyses with StatsDirect  2.8.0 (StatsDirect Ltd., Cheshire, UK) and Microsoft Office Excel 2010 (Microsoft Corporation).
Study's limitations
The legal framework for personal data protection of patients, their unavailable medication history and non-existence of the e-Health in CZ and SK limited our study with regards to community pharmacist's support on specific patient, his/ her specific type of problem/s and pharmacotherapeutic outcome/s. Therefore, collected data from the pharmacists' responses give an estimate on the medication adherence promotion provided in respective pharmacies participating in the questionnaire survey.
RESultS
Consultations, counselling and DRPs
The majority of pharmacists in our data set stated that they provide consultations or counselling to patients (CZ: 69.2%, SK: 92.7%). We investigated whether these activities could be associated with resolving DRPs. Unlike CZ, in SK there was a significant and high concurrence in answers (answer type yesyes) that showed that if SK pharmacists provide consultations, they do so in order to help patients in finding solution to DRPs and, on the other hand, those pharmacists that do not provide consultations, do not engage with DRP-solving activities (answer type no-no), P < 0.0001 (Table 1) . In registering DRPs, we found a statistically significant difference in favour of SK pharmacists (P = 0.008). Pharmacists do register DRPs, although there is no e-Health currently at place in either country. Such registrations therefore tend to be non-systematic and rare. Due to the small number of responses, we could not assess to what extent DRPs are registered in either paper or electronic form. In both countries, pharmacists deal with DRPs at a similar rate of frequency, usually either daily or 2 to 3 times per week (P = 0.052). Just about half of the pharmacists (50.8%) in both countries register loyal patients and their revisits. Loyal patients represented more than 50% of all patients visiting pharmacies.
We did not find a correlation between revisits of patients and resolving DRPs in the data sets.
Support of medication adherence
Each evaluated activity of pharmacists aimed at an improvement of medication adherence, persistence or concordance, was scored with one point. The overall relative score for all activities combined could range from 0 to 4 points. The more intensive the support of a pharmacist was, the higher the score. We did not observe significant differences between CZ and SK in support of the adherence, persistence or concordance. Support for adherence reached the average level with the highest scoring value in both countries. Support for adherence (CZ: 1.95; SK: 1.93) was significantly higher than support for persistence (CZ: 1.18;SK: 1.07), and was also higher than support for concordance (CZ: 1.28;SK: 1.27), (Fig. 2) . We used the adopted Morisky scale to estimate with what intensity non-adherence risk could be reduced. We evaluated this from the perspective of the pharmacist, who addresses one or more critical areas of a patient's attitude and behaviour, which can help to uncover patient's compliance with a prescribed pharmacotherapy. In CZ, we measured that the overall average score was marginally higher than for SK. It reached the medium degree of support in both data sets [CZ: 2.29 and SK: 2.22; P = 0.739; 95% CI for the difference in mean scores went from (-0.35) to 0.49]. The difference was attributed to a higher score achieved by CZ pharmacists concerning the reduction of any risk that patient would not comply with the recommended time of medication use (P = 0.032; the lower and upper limits of the 95% CI for the odds ratio were 1.02 and 5.09). Other risk factors were comparable with SK. These include forgetfulness, missing medication or termination of medication use due to adverse reaction or, on the contrary, because therapeutic effect has already been attained (Table 2) .
Relationship analysis between estimated support for medication adherence and technical and personnel characteristics of pharmacies
The survey demonstrated that geographic parameters of location (in relation to the number of inhabitants) or size of pharmacies by the number of professional employees, namely, The SK pharmacists, while using consultation rooms, were engaged more with adherencerelated issues as compared to CZ (P = 0.037; Cramér's V = 0.37).
On the other hand, the CZ pharmacists use the consultancy rooms -if they are equipped with -more frequently than SK pharmacists, although at the margin of significance (P = 0.058). Majority of the survey's respondents had a qualification in pharmacy (CZ: 88%; SK: 83%). As far as the number of years of professional experience (practice) of the pharmacists (i.e., the respondents) is concerned, our data showed that the respondents mostly had between 20 and 29 years of practice in both data sets. When it comes to the number of years of professional experience, we found a difference between SK and CZ -there is a stronger relationship between the number of years of experience and adherence support in SK (p = 0.029), whereas we could not establish a correlation in CZ (P = 0.175). Moreover, in the SK data set, we also found a strong linear relationship between the number of years of professional experience and medication adherence support (P = 0.0496) ( Table 3) . We also found a strong correlation between the preferential source of information for pharmacists as the Recommended Procedures authorized by the Czech Chamber of Pharmacists (2010) and support for adherence by CZ pharmacists (P = 0.005), in comparison to SK pharmacists, where a similar source of information was not available. We observed, that majority of pharmacists cooperated with healthcare practitioners in solving the DRPs in both countries (CZ: 78.6%; SK: 82.9%; P = 0.51; 95% CI 0.253 to 2.023) ( Table  4) . A close relationship between adherence and DRPs was confirmed in the CZ data set (P = 0.00015) as compared to the SK data set, despite Cramer's V showing a weak association (0.334). It is possible, that if data sets were larger, we would not observe the difference between CZ and SK data sets. (Table 5 ).
dISCuSSIon
Results of the questionnaire survey matched with our prediction that pharmacists had been involved in the medication adherence support, as similarly published by other authors (Lau et al., 2010 , Santschi et al., 2012 , Vlček, et al., 2009 ). We assume that pharmacists can support patient adherence and they are able to reduce the risk of patients´ non-adherence, reaching in average the medium degree. We found that support for medication adherence has been provided to a greater degree than support for other forms of patients' adherence attitudes towards treatment, such as persistence and concordance. (Herein, we refer to ). Despite strong differences in terms of the legislative requirements in the two countries, our finding showed that CZ pharmacies use consultation rooms more frequently -though the frequency was only marginally higher than SK pharmacies. This finding indicates that legislation is not the unique factor that influences the extent to which pharmaceutical care is provided. In this respect, other factors, both personal and professional, also have significant importance. The difference in the legislative and societal development of pharmaceutical care in the two countries reveals potential that we could elaborate upon to increase support for medication adherence by pharmacists. From the perspective of personnel characteristics of pharmacy, the degree of support for adherence was not dependent upon the number of professional workers. However, in the SK data set, we found that the number of years of professional experience increase the probability that the pharmacists approach patients, discuss a prescribed treatment and try to help to resolve patients' DRPs. We assume, that SK pharmacies, in comparison to CZ pharmacies, provide such a kind of consultations that are closely linked to resolving DRPs in collaboration with healthcare practitioners. (2015) . Non-adherence very likely represents the common denominator of these problems. The risk of non-adherence should be detected and resolved responsibly, whereas cooperation between pharmacists and healthcare practitioners gives a solid ground for furnishing effective and prompt solutions to the identified problems.
To examine other possibilities of how to increase support for patient adherence, the specific profile of risk patients could be considered, which the pharmacists could focus on. Our findings indicated that there is a close association between support for medication adherence and personnel capacities (factors) of pharmacy. These factors mostly concern the professional experience of pharmacists and the quality of consultation and counselling, which might be efficiently supported by training and/or authorized sources of recommendations for pharmacists such as Recommended Procedures of the Czech Pharmacists' Association available since 2010. Recently, the Association opened new courses in DRPs, enabling additional services, which include recommendations in terms of dosage and therapeutic regime. The Association is planning to extend its recommendations into other areas of pharmaceutical professional consultancy. Since 2013, the Czech Chamber of Pharmacists offers a mobile application mapping the pharmacies with consultation rooms. All these initiatives, as mentioned hereby, represent useful electronic tools that could enable the pharmacists to address patients' adherence and vice-versa, in more effective way.
In general, we can assume that the support for medication adherence is provided in both CZ and SK pharmacies. It reaches a medium degree and develops in the right direction -towards concordance in the pharmacist-patient relationship. The responses to our survey suggest that the development of interdisciplinary cooperation with other healthcare professionals, mostly medical practitioners, remains challenging (non-systematic and rare registration of DRPs). The e-Health system will soon be introduced in both countries, and is expected to become an important factor in this dimension, as it will enable connection with relevant data and information. It is also recognizable that recommended practice, education in DRPs and life-long education of pharmacists represent important pre-requisites for further development of pharmaceutical care in medication adherence support.
survey in CZ and SK. Based on the pharmacists' responses, we assumed a medium degree of support for patient adherence, predominantly provided in order to resolve DRPs in both countries. We can also point out that education and experience for pharmacists could be one of the crucial factors in ensuring support for adherence. Its progress might also be accelerated through the use of information technologies, as research in multiple countries has also demonstrated recently. We conclude that our findings can offer a solid base for further investigations aimed at evidence-based interventions in this area, and so to contribute to pharmaceutical care development. 
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